3 Cancer Treatment Stocks to Buy in March [The Motley Fool]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: The Motley Fool
3 Cancer Treatment Stocks to Buy in March There has been tremendous progress in the battle against cancer, but it remains the second leading cause of death in the U.S., behind heart disease. That means there is plenty of work left to be done. So which cancer-focused companies are worth watching? We asked three Motley Fool healthcare contributors to weigh in, and they called out Blueprint Medicines ( NASDAQ:BPMC Halozyme Therapeutics NASDAQ:HALO Merck NYSE:MRK Image source: Getty Images. A map to better cancer drugs Todd Campbell Eli Lilly acquisition A slate of companies could benefit from this shift in how we treat disease, but Blueprint Medicines is my favorite to buy now. Like Loxo Oncology, Blueprint Medicines is developing drugs targeting genetic mutations. Its most advanced therapy is avapritinib, a possible treatment for gastrointestinal stromal tumors (GIST) and systemic mastocytosis (SM) that inhibits the protein kinases KIT and PDGFRA. Data from trials in advanced GIST is ex
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024PR Newswire
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsPR Newswire
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $114.00 price target on the stock.MarketBeat
BPMC
Earnings
- 2/15/24 - Beat
BPMC
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEF
- 4/25/24 - Form 8-K
- BPMC's page on the SEC website